Literature DB >> 19247302

Febuxostat.

Eliseo Pascual, Francisca Sivera, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19247302     DOI： 10.1038/nrd2831

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  13 in total

Review 1.  Pathogenesis of gout.

Authors:  Hyon K Choi; David B Mount; Anthony M Reginato
Journal:  Ann Intern Med       Date:  2005-10-04       Impact factor: 25.391

2.  Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout.

Authors:  Eliseo Pascual; Francisca Sivera
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

3.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Authors:  Michael A Becker; H Ralph Schumacher; Robert L Wortmann; Patricia A MacDonald; Denise Eustace; William A Palo; Janet Streit; Nancy Joseph-Ridge
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.

Authors:  Ken Okamoto; Bryan T Eger; Tomoko Nishino; Shiro Kondo; Emil F Pai; Takeshi Nishino
Journal:  J Biol Chem       Date:  2002-11-05       Impact factor: 5.157

Review 5.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

6.  Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).

Authors:  T R Mikuls; J T Farrar; W B Bilker; S Fernandes; K G Saag
Journal:  Rheumatology (Oxford)       Date:  2005-05-03       Impact factor: 7.580

7.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

Authors:  Fernando Perez-Ruiz; Marcelo Calabozo; Jose I Pijoan; Ana M Herrero-Beites; Ana Ruibal
Journal:  Arthritis Rheum       Date:  2002-08

8.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Authors:  M K Reinders; C Haagsma; T L Th A Jansen; E N van Roon; J Delsing; M A F J van de Laar; J R B J Brouwers
Journal:  Ann Rheum Dis       Date:  2008-07-16       Impact factor: 19.103

9.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Authors:  H Ralph Schumacher; Michael A Becker; Robert L Wortmann; Patricia A Macdonald; Barbara Hunt; Janet Streit; Christopher Lademacher; Nancy Joseph-Ridge
Journal:  Arthritis Rheum       Date:  2008-11-15

10.  Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.

Authors:  Y Osada; M Tsuchimoto; H Fukushima; K Takahashi; S Kondo; M Hasegawa; K Komoriya
Journal:  Eur J Pharmacol       Date:  1993-09-14       Impact factor: 4.432
View more
  11 in total

Review 1.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.

Authors:  Fraser F Fleming; Lihua Yao; P C Ravikumar; Lee Funk; Brian C Shook
Journal:  J Med Chem       Date:  2010-08-30       Impact factor: 7.446

2.  Pegloticase.

Authors:  Naomi Schlesinger; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

3.  Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.

Authors:  Charles R Esther; Lidija Turkovic; Tim Rosenow; Marianne S Muhlebach; Richard C Boucher; Sarath Ranganathan; Stephen M Stick
Journal:  Eur Respir J       Date:  2016-11-11       Impact factor: 16.671

4.  HCl•DMPU-Assisted One-pot and Metal-free Conversion of Aldehydes to Nitriles.

Authors:  Sagar R Mudshinge; Chinmay S Potnis; Bo Xu; Gerald B Hammond
Journal:  Green Chem       Date:  2020-05-14       Impact factor: 10.182

Review 5.  Dietary supplements for chronic gout.

Authors:  Mariano Andrés; Francisca Sivera; Rachelle Buchbinder; Jordi Pardo Pardo; Loreto Carmona
Journal:  Cochrane Database Syst Rev       Date:  2021-11-12

Review 6.  Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.

Authors:  Arrigo F G Cicero; Federica Fogacci; Raffaele Ivan Cincione; Giuliano Tocci; Claudio Borghi
Journal:  Med Princ Pract       Date:  2020-10-09       Impact factor: 1.927

Review 7.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

8.  Crystal structure of febuxostat-acetic acid (1/1).

Authors:  Min Wu; Xiu-Rong Hu; Jian-Ming Gu; Gu-Ping Tang
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-09

9.  A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.

Authors:  Meenu Pichholiya; Arvind Kumar Yadav; S K Luhadia; Jameela Tahashildar; M L Aseri
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

Review 10.  Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.

Authors:  Arrigo F G Cicero; Federica Fogacci; Masanari Kuwabara; Claudio Borghi
Journal:  Medicina (Kaunas)       Date:  2021-01-10       Impact factor: 2.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.